Header 1 Page 1
Header 2 Table
# Page 1  
## Table
---
| المادة: | علوم | الحياة | - | لغة | فرنسية | الشهادة: | الثانوية | العامة | الفرع: | الآداب | والإنسانيات | نموذج | رقم | 2019/1 | المدّة | : | ساعة | واحدة | الهيئة | الأكاديميّة | المشتركة | قسم | : | العلوم | Traiter | les | trois | exercices | suivants. | Exercice | 1: | (6.5 | points) | المركز | التربوي | للبحوث | والإنماء | Paralysie | Musculaire | chez | les | Vers | Caenorhabditis | elegans | est | un | petit | ver | qui | sert | de | modèle | animal | pour | étudier | le | fonctionnement | de | la | synapse | neuromusculaire. | Le | document | 1 | présente | quelques | étapes | du | fonctionnement | synaptique | dans | un | ver | normal. | 1. | Citer, | en | se | référant | au | document | 1, | les | étapes | de | la | transmission | synaptique | qui | conduisent | à | la | contraction | musculaire. | 2. | Préciser | si | la | synapse | présentée | dans | le | document | 1 | est | excitatrice | ou | inhibitrice. | Motoneurone | Fente | 2 | H | 1- | Arrivée | du | message | nerveux | M | Récepteur | . | Neurotransmetteur: | Acetylcholine | C | Vésicule | de | sécrétion | 1 | Membrane | 3 | synaptique | Cellule | musculaire | présynaptique | 4 | Membrane | M | postsynaptique | 5 | Contraction | musculaire | Document | 1 | Unc-13 | est | une | variété | du | ver | Caenorhabditis | elegans | qui | présente | une | paralysie | musculaire | totale | reliée | à | un | dysfonctionnement | de | la | transmission | synaptique. | Les | études | suivantes | ont | été | réalisées | dans | le | but | de | découvrir | la | cause | de | ce | dysfonctionnement. | Etude | 1: | On | injecte | de | l'acétylcholine | radioactive | dans | la | fente | synaptique | des | plaques | motrices | des | deux | vers, | normal | et | Unc-13. | De | la | radioactivité | est | retrouvée | sur | la | membrane | postsynaptique | et | des | contractions | musculaires | sont | observées | dans | chacun | de | ces | vers. | 3. | Montrer | que | la | paralysie | des | vers | Unc-13 | n'est | pas | liée | à | un | défaut | des | récepteurs | postsynaptiques. | Avant | stimulation | Nombre | total | de | vésicules | présynaptiques | Etude | 2 | : | Le | document | 2 | présente | le | nombre | total | de | vésicules | de | sécrétion | présynaptiques | contenant | l'acétylcholine | dans | les | deux | vers, | avant | et | après | une | stimulation | électrique | efficace | du | neurone | moteur | innervant | le | muscle. | 80 | 75 | 40 | 0 | Ver | Ver | normal | Unc-13 | 4.1. | Analyser | les | résultats | obtenus. | 4.2. | Dégager | la | cause | de | la | paralysie | chez | les | vers | Unc-13. | Après | stimulation | - | Nombre | total | de | vésicules | présynaptiques | 80 | 75 | ₣ |
---
2 | : | Le | document | 2 | présente | le | nombre | total | de | vésicules | de | sécrétion | présynaptiques | contenant | l'acétylcholine | dans | les | deux | vers, | avant | et | après | une | stimulation | électrique | efficace | du | neurone | moteur | innervant | le | muscle. | 80 | 75 | 40 | 0 | Ver | Ver | normal | Unc-13 | 4.1. | Analyser | les | résultats | obtenus. | 4.2. | Dégager | la | cause | de | la | paralysie | chez | les | vers | Unc-13. | Après | stimulation | - | Nombre | total | de | vésicules | présynaptiques | 80 | 75 | ₣ | 40 | 30 | 0 | Ver | Ver | normal | Unc-13 | Document | 2 | Exercice | 2 | : | (7 | points) | Thérapie | de | vitamine | C | et | cancer | L'acide | ascorbique | ou | la | vitamine | C | est | un | nutriment | essentiel | pour | la | santé. | Il | est | présent | naturellement | dans | certains | aliments, | en | particulier | les | fruits | et | les | légumes. | C'est | un | antioxydant | qui | ralentit | le | processus | d'oxydation, | et | qui | prévient | les | dégâts | causés | aux | cellules. | 1. | Relever | du | texte | le | rôle | des | antioxydants. | 1 |
---
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
---
Header 1 Page 2
Header 2 Table
# Page 2  
## Table
---
| Dans | le | cadre | de | recherches | concernant | l'importance | d'un | apport | de | vitamine | C | aux | patients | atteints | de | cancer, | on | a | réalisé | les | études | suivantes | : | Etude | 1 | : | Afin | de | montrer | l'effet | de | l'apport | de | vitamine | C | sur | l'intensité | des | effets | indésirables | liés | à | la | chimiothérapie, | une | recherche | est | menée | en | Allemagne | pendant | 4 | semaines | sur | 125 | patientes | atteintes | d'un | cancer | du | sein. | Les | résultats | figurent | dans | le | document | 1. | 2. | Interpréter | les | résultats | obtenus | (document | 1). | Etude | 2 | : | Une | autre | recherche | a | été | réalisée | pour | montrer | l'effet | de | la | vitamine | C | sur | la | survie | de | neuf | lignées | de | cellules | cancéreuses | et | celle | de | quatre | types | de | cellules | normales. | Les | cellules | testées | ont | été | placées | dans | un | milieu | de | culture | additionné | de | vitamine | C | pendant | 1 | heure. | Les | résultats | sont | présentés | dans | le | document | 2. | Intensité | des | effets | secondaires | de | la | chimiothérapie | (u.a) | 6 | 2.5 | 2.37 | 1.8 | 0.5 | 0.2 | Nausées | Pertes | d'appétit | Fatigue | Femmes | traitées | à | la | vitamine | C | Femmes | non | traitées | à | la | vitamine | C | Document | 1 | 3. | Construire | une | courbe | montrant | les | variations | du | pourcentage | de | survie | des | cellules | normales | et | cancéreuses | en | fonction | du | temps | (document | 2). | 4. | Interpréter | les | résultats | présentés | dans | le | document | 2. | Document | 2 | 5. | Déterminer | les | effets | de | la | vitamine | C | sur | la | santé | des | patients | atteints | de | cancer. | Temps | (minutes) | 0 | 10 | 20 | 30 | 40 | 50 | 60 | Pourcentage | de | survie | (%) | Cellules | normales | 100 | 100 | 100 | 100 | 100 | 100 | 100 | Cellules | cancéreuses | 100 | 90 | 80 | 70 | 60 | 50 | 40 | Exercice | 3 | : | (6.5 | points) | Maladie | Coronarienne | La | maladie | coronarienne | est | caractérisée | par | un | rétrécissement | des | artères | coronaires | qui | alimentent | le | cœur | en | dioxygène | et | en | nutriments. | Ce | rétrécissement | est | dû | à | la | formation | d'une | plaque | d'athérome | (athérosclérose). | Le | cholestérol | dans | le | sang | se | présente | sous | deux | formes | majeures | : | les | lipoprotéines | de | basse | densité | ou | LDL | et | les | lipoprotéines | de | haute | densité | ou | HDL. | L'une | de | ces | formes | est | qualifiée | de | « | mauvais | cholestérol» | car | elle | facilite | la | formation | de | plaques | d'athérome. | 1. | Indiquer: | 1.1 | La | cause | de | la | maladie | coronarienne. | 1.2 | Les | formes | de | cholestérol | transportées | par | le | sang | et
---
plaque | d'athérome | (athérosclérose). | Le | cholestérol | dans | le | sang | se | présente | sous | deux | formes | majeures | : | les | lipoprotéines | de | basse | densité | ou | LDL | et | les | lipoprotéines | de | haute | densité | ou | HDL. | L'une | de | ces | formes | est | qualifiée | de | « | mauvais | cholestérol» | car | elle | facilite | la | formation | de | plaques | d'athérome. | 1. | Indiquer: | 1.1 | La | cause | de | la | maladie | coronarienne. | 1.2 | Les | formes | de | cholestérol | transportées | par | le | sang | et | le | rôle | de | chaque | forme. | 2. | Justifier | l'affirmation | : | « | l'excès | d'aliments | riches | en | lipides | favorisant | la | production | de | LDL, | comme | le | lait, | les | œufs | et | la | viande, | augmente | le | risque | d'atteinte | par | une | crise | cardiaque | ». | Afin | de | faire | baisser | le | risque | de | maladie | coronarienne, | les | diététiciens | recommandent | une | alimentation | saine | enrichie | en | stérols | végétaux. | Les | stérols | végétaux | sont | des | substances | naturellement | présentes | en | petites | quantités | dans | de | nombreux | produits | végétaux | comme | les | légumes, | les | fruits, | les | noix | et | les | grains. | Le | document | joint | montre | l'effet | de | la | prise | de | stérols | végétaux | sur | le | taux | de | LDL. | 1 | Reduction | du | taux | de | LDL | (%) | 11 | - | 10 | 8 | 6 | 5 | 4 | 210 | 2 | 1 | 0,5 | 1 | 1,5 | 2 | 2,5 | 3 | Prise | de | stérols | végétaux | (g/jour) | 3. | Interpréter | les | résultats | présentés | dans | le | document | joint. | 4. | Expliquez, | en | vous | référant | à | tout | ce | qui | précède, | pourquoi | les | diététiciens | recommandent | de | consommer | des | stérols | végétaux. | 2 |
---
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
---
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
---
Header 1 Page 3
Header 2 Table
# Page 3  
## Table
---
| المادة: | علوم | الحياة | - | لغة | فرنسية | الشهادة: | الثانوية | العامة | الفرع: | الآداب | والإنسانيات | نموذج | رقم | 2019/1 | المدّة | : | ساعة | واحدة | الهيئة | الأكاديميّة | المشتركة | قسم | : | العلوم | المركز | التربوي | للبحوث | والإنماء | أسس | التصحيح: | Partie | de | l'exercice | Exercice | 1 | (6,5 | points) | Paralysie | musculaire | chez | les | vers | Note | 1 | Les | étapes | de | la | transmission | synaptique | menant | à | la | contraction | musculaire | : | 1. | Arrivée | du | message | nerveux | au | niveau | des | boutons | terminaux | du | motoneurone. | 2. | Fusion | des | vésicules | de | sécrétion | contenant | le | neurotransmetteur, | l'acétylcholine, | avec | la | membrane | présynaptique. | 3. | Exocytose | du | neurotransmetteur, | l'acétylcholine, | dans | la | fente | synaptique. | 4. | Fixation | de | l'acétylcholine | aux | récepteurs | postsynaptiques | sur | la | membrane | postsynaptique | de | la | cellule | musculaire. | 5. | Cette | fixation | induit | une | contraction | musculaire. | 2 | 2 | La | synapse | est | excitatrice | puisque | la | fixation | du | neurotransmetteur, | l'acétylcholine, | sur | ses | récepteurs | postsynaptiques | spécifiques, | induit | une | réponse | au | niveau | du | muscle | : | une | contraction. | 1 | 3 | L'injection | d'acétylcholine | radioactive | dans | la | fente | synaptique | entraîne | une | contraction | musculaire | chez | les | deux | vers, | le | ver | normal | et | Unc-13, | et | de | la | radioactivité | est | révélée | sur | les | membranes | post | synaptiques. | Ceci | signifie | que | les | récepteurs | postsynaptiques | des | vers | Unc-13 | sont | sensibles | à | l'acétylcholine, | et | par | conséquence, | ils | sont | normaux. | Ainsi, | la | paralysie | de | ces | vers | n'est | pas | liée | à | un | défaut | de | ces | récepteurs. | 1,5 | 4.1 | Avant | la | stimulation | électrique, | le | nombre | total | de | vésicules | présynaptiques | contenant | de | l'acétylcholine | est | approximativement | le | même | dans | le | ver | normal, | 80 | vésicules, | et | dans | le | ver | Unc-13, | 75 | vésicules. | Mais, | après | la | stimulation | efficace | du | neurone | moteur | innervant | les | muscles | dans | les | 2 | vers, | ce | nombre | diminue | chez | le | ver | normal | à | 30 | vésicules, | tandis | que | pour | Unc-13, | il | reste | inchangé, | 75 | vésicules. | 1,5 | 4.2 | La | paralysie | musculaire | chez | les | vers | Unc-13 | est | causée | par | l'absence | de | l'exocytose | du | neurotransmetteur | (l'acétylcholine) | dans | la |
---
| 80 | vésicules, | et | dans | le | ver | Unc-13, | 75 | vésicules. | Mais, | après | la | stimulation | efficace | du | neurone | moteur | innervant | les | muscles | dans | les | 2 | vers, | ce | nombre | diminue | chez | le | ver | normal | à | 30 | vésicules, | tandis | que | pour | Unc-13, | il | reste | inchangé, | 75 | vésicules. | 1,5 | 4.2 | La | paralysie | musculaire | chez | les | vers | Unc-13 | est | causée | par | l'absence | de | l'exocytose | du | neurotransmetteur | (l'acétylcholine) | dans | la | fente | synaptique. | 0,5 | Partie | de | l'exercice | Exercice | 2 | (7 | points) | Thérapie | de | vitamine | C | et | cancer | Note | 1 | Un | antioxydant | est | une | substance | qui | ralentit | le | processus | d'oxydation | et | qui | prévient | les | dégâts | causés | aux | cellules. | 1 | 2 | Les | intensités | des | effets | secondaires | de | la | chimiothérapie, | les | nausées, | la | perte | d'appétit | et | la | fatigue, | sont | de | 1.8 | u.a, | 2.3 | u.a | et | 6 | u.a | respectivement, | chez | les | femmes | non | traitées | à | la | vitamine | C. | Par | contre, | ces | intensités | diminuent | jusqu'à | 0.2 | u.a, | 0.5 | u.a | et | 2.5 | u.a | respectivement | quand | les | femmes | sont | traitées | à | la | vitamine | C. | Ainsi, | le | traitement | à | la | vitamine | C | réduit | les | effets | indésirables | liés | à | la | chimiothérapie | chez | les | patients | cancéreux. | 1,5 | 3 |
---
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
---
Header 1 Page 4
Header 2 Table
# Page 4  
## Table
---
| 3 | Courbe | montrant | le | pourcentage | de | survie | des | cellules | traitées | avec | la | vitamine | C | en | fonction | du | temps. | 100 | Pourcentage | de | survie | (%) | Cellules | normales | 90 | 80 | 20 | % | 70 | Cellules | cancéreuses | 60 | 50 | 10 | min | 2 | 40 | 30 | 20 | 10 | Temps | (min) | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 4 | Les | résultats | dans | le | document | 2 | montrent | que | la | vitamine | C | réduit | le | pourcentage | de | survie | des | cellules | cancéreuses | de | 100% | à | 40%, | alors | qu'elle | n'a | aucun | effet | sur | la | survie | des | cellules | normales | (100%). | Ceci | signifie | que | la | vitamine | C | facilite | la | destruction | des | cellules | cancéreuses | sans | nuire | aux | cellules | normales. | 1 | 5 | La | vitamine | C | agit | comme | un | antioxydant | qui | ralentit | le | processus | d'oxydation, | et | qui | prévient | les | dégâts | causés | aux | cellules. | En | plus, | elle | réduit | l'intensité | des | effets | secondaires | de | la | chimiothérapie | et | elle | facilite | la | destruction | des | cellules | cancéreuses | sans | nuire | aux | cellules | normales. | Ainsi, | la | vitamine | C | présente | une | action | positive | pour | les | patients | cancéreux | en | améliorant | leur | qualité | de | vie, | en | ralentissant | la | progression | du | cancer | et | en | préservant | leurs | cellules. | 1,5 | Partie | de | l'exercice | Exercice | 3 | (6.5 | points) | Maladie | coronarienne | Note | 1.1 | La | maladie | coronarienne | est | causée | par | la | formation | de | plaques | d'athérome | pouvant | bloquer | les | artères | coronaires. | 0.5 | 1 | 1.2 | Le | cholestérol | est | transporté | par | le | sang | sous | deux | formes: | Lipoprotéines | de | basse | densité | ou | LDL | et | lipoprotéines | de | haute | densité | ou | HDL. | Le | HDL | transporte | l'excès | de | cholestérol | des | tissus | vers | le | foie | pour | prévenir | son | accumulation | dans | le | sang. | Le | LDL | dépose | le | cholestérol | sur | la | paroi | interne | des | artères, | où | il | s'accumule, | causant | la | formation | de | plaques | d'athérome. | 2 | 2 | La | consommation | d'aliments | riches | en | lipides | tels | que | le | lait, | les | œufs | et | la | viande | aboutit | à | une | augmentation | du | taux | de | LDL | dans | le | sang. | Le | taux | excessif | de | LDL | favorise | le | dépôt | et | l'accumulation | de | cholestérol | sur | la | paroi | interne | des | artères, | ce | qui | provoque | la | formation | de | plaques | d'athérome | causant | un | rétrécissement | des | artères | coronaires. | Ce | rétrécissement | aboutit | à | une | diminution | des | quantités | d'oxygène | et | de | nutriments | arrivant | aux | cellules, | et | éventuellement | à | une | augmentation | du | risque | d'atteinte
---
le | lait, | les | œufs | et | la | viande | aboutit | à | une | augmentation | du | taux | de | LDL | dans | le | sang. | Le | taux | excessif | de | LDL | favorise | le | dépôt | et | l'accumulation | de | cholestérol | sur | la | paroi | interne | des | artères, | ce | qui | provoque | la | formation | de | plaques | d'athérome | causant | un | rétrécissement | des | artères | coronaires. | Ce | rétrécissement | aboutit | à | une | diminution | des | quantités | d'oxygène | et | de | nutriments | arrivant | aux | cellules, | et | éventuellement | à | une | augmentation | du | risque | d'atteinte | par | une | crise | cardiaque. | 2 | 3 | La | réduction | du | taux | de | LDL | augmente | progressivement | de | 1% | à | 11% | au | fur | et | à | mesure | que | la | consommation | de | stérols | végétaux | augmente | de | 0,5 | g | / | jour | à | 3 | g | / | jour. | Cela | indique | que | les | stérols | végétaux | favorisent | la | réduction | de | la | teneur | de | LDL | dans | le | sang. | 1 | 4 | Une | forte | teneur | en | LDL | dans | le | sang | favorise | la | formation | de | plaques | d'athérome | qui | obstruent | les | artères | coronaires | augmentant | ainsi | le | risque | d'une | crise | cardiaque. | Par | contre, | une | alimentation | riche | en | stérols | végétaux | réduit | le | taux | de | LDL | dans | le | sang, | ce | qui | réduit | le | risque | de | formation | de | plaques | d'athérome, | et | réduit | en | conséquence | celui | de | la | survenue | d'une | crise | cardiaque. | Ainsi, | les | stérols | végétaux | préviennent | les | maladies | coronariennes, | raison | pour | laquelle | leur | consommation | est | recommandée | par | les | diététiciens. | 1 | 4 |
---
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
---
